Literature DB >> 972269

Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients.

J C Péchère, R Dugal.   

Abstract

The pharmacokinetics of intravenously administered tobramycin, an aminoglycoside antibiotic, were studied in 16 volunteers with normal renal function and 10 patients with different degrees of renal impairment. In all subjects, the disappearance of tobramycin from serum followed first-order kinetics, and the elimination rate constant decreased proportionally with increasing degree of renal impairment. The half-life average 82 min in normal subjects (endogenous creatinine clearance, greater than 80 ml/1.73 m2 per min) and was 33.7 hr in a totally anephric subject. Linear relations were defined between the half-life of tobramycin in serum and the reciprocal of the endogenous creatinine clearance and between the half-life of the drug and the concentration of serum creatinine. These relations may be used for dosage adjustment in patients with renal impairment. In hemodialyzed patients, the half-life decreased six- to ninefold during dialysis for 6 hr. The extent of tobramycin elimination by hemodialysis may be predicted from relations established between the elimination of tobramycin and that of creatinine and blood urea nitrogen. Dosage schedules must be compatible with the pharmacologic and pharmacokinetic properties of the antibiotic.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 972269     DOI: 10.1093/infdis/134.supplement_1.s118

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

2.  Pharmacokinetics of intravenous amikacin after rapid and slow infusion with special reference to hemodialysis.

Authors:  J C Pechere; R Dugal; M M Pechere
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

3.  Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis.

Authors:  J C Pechere; R Dugal; M M Pechere
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

5.  Hemodialysis elimination rates and clearance of gentamicin and tobramycin.

Authors:  G R Matzke; C E Halstenson; W F Keane
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

6.  Altered tobramycin pharmacokinetics during chemoprophylaxis in bladder surgery.

Authors:  F Bressolle; P Joubert; A Gouby; P Costa; M Laracine; T Rebière
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 7.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

8.  Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

Authors:  J Fabre; H M Fox; P Dayer; L Balant
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

9.  Comparative distribution of gentamicin, tobramycin, sisomicin, netilmicin, and amikacin in interstitial fluid in rabbits.

Authors:  C Carbon; A Contrepois; S Lamotte-Barrillon
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

Review 10.  Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis.

Authors:  John Lam; Steven Vaughan; Michael D Parkins
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2013-11-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.